Table 1 Demographics and relevant features of untreated RTT vs patients treated with mirtazapine (MTZ)
From: Protective role of mirtazapine in adult female Mecp2+/− mice and patients with Rett syndrome
Variable | Untreated RTT | MTZ-treated RTT | p value |
|---|---|---|---|
N | 40 | 40 | |
Age (years) | 22.3 ± 7.2 | 23.9 ± 7.9 | 0.354 |
Clinical phenotype | 0.079 | ||
Typical | 39 (97.5%) | 37 (92.5%) | |
Preserved speech variant (PSV) | 1 (2.5%) | 3 (7.5%) | |
MECP2 mutation category | 0.223 | ||
Missense | 17 (42.5%) | 13 (32.5%) | |
Early truncating | 15 (37.5%) | 17 (42.5%) | |
Late truncating | 4 (10%) | 9 (22.5%) | |
Gene deletions | 4 (10%) | 1 (2.5%) | |
Rett syndrome clinical severity scale (RCSS) | 24.7 ± 8.2 | 22.6 ± 6.5 | 0.206 |
Motor behavioral assessment scoring scale (MBAS) | 56.4 ± 9.0 | 58.7 ± 6.5 | 0.596 |
I Social-behavioral domain | 22.7 ± 6.1 | 24.0 ± 6.9 | 0.374 |
II Orofacial/respiratory domain | 13.6 ± 2.8 | 14.2 ± 3.9 | 0.417 |
III Motor and clinical features domain | 20.1 ± 3.3 | 20.5 ± 1.0 | 0.450 |